# Nuclide record monopar (company). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/companies/monopar/>
  a schema:Organization ;
  nuclide:kind "company" ;
  schema:identifier "monopar" ;
  schema:name "Monopar Therapeutics"@en ;
  schema:alternateName "Monopar Therapeutics Inc."@en, "Monopar"@en ;
  schema:description "Monopar is a Chicago-area biotech that took the mucositis drug validive into a phase 3 trial in head and neck cancer, which failed in 2023, and now develops radiopharmaceuticals against the uPAR protein."@en ;
  schema:url <https://nuclide.cc/companies/monopar/>, <https://www.monopartx.com> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://www.monopartx.com>, <https://clinicaltrials.gov/search?lead=Monopar%20Therapeutics%20Inc.> ;
  nuclide:tag "ctgov-sponsor" ;
  schema:addressCountry "US" ;
  nuclide:technologies <https://nuclide.cc/technologies/radioligand-therapy/> .